{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:53:30Z","timestamp":1790715210125,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40262-021-01090-2","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T19:03:48Z","timestamp":1642705428000},"page":"465-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-2131","authenticated-orcid":false,"given":"Dominick J.","family":"Angiolillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2146-9820","authenticated-orcid":false,"given":"Jayne","family":"Prats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymios N.","family":"Deliargyris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Scheiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"Kimmelstiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph. Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Rosengart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"1090_CR1","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.2174\/138945011797635858","volume":"12","author":"SR Steinhubl","year":"2011","unstructured":"Steinhubl SR. Historical observations on the discovery of platelets, platelet function testing and the first antiplatelet agent. Curr Drug Targets. 2011;12:1792\u2013804.","journal-title":"Curr Drug Targets"},{"key":"1090_CR2","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1161\/CIRCULATIONAHA.110.963843","volume":"123","author":"V Fuster","year":"2011","unstructured":"Fuster V, Sweeny JM. Aspirin a historical and contemporary therapeutic overview. Circ. 2011;123:768\u201378.","journal-title":"Circ"},{"key":"1090_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/newbio231232a0","volume":"231","author":"JR Vane","year":"1971","unstructured":"Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232\u20135.","journal-title":"Nat New Biol"},{"key":"1090_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists Collaborative","year":"2002","unstructured":"Antithrombotic Trialists Collaborative. Collaborative meta\u00adanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002;324:71\u201386.","journal-title":"BMJ"},{"key":"1090_CR5","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596\u2013646.","journal-title":"Circulation"},{"key":"1090_CR6","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","volume":"124","author":"SC Smith Jr","year":"2011","unstructured":"Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458\u201373.","journal-title":"Circulation"},{"key":"1090_CR7","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.jacc.2016.11.007","volume":"69","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69:e71-126.","journal-title":"J Am Coll Cardiol"},{"key":"1090_CR8","doi-asserted-by":"crossref","unstructured":"Powers WJ, Rabinstein AA, Ackerson T, et al; on behalf of the American Heart Association Stroke Council. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2019;50(12):e344\u2013e418.","DOI":"10.1161\/STR.0000000000000211"},{"key":"1090_CR9","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.2147\/IJGM.S326929","volume":"14","author":"HM Kedir","year":"2021","unstructured":"Kedir HM, Sisay EA, Abiye AA. Enteric-coated aspirin and the risk of gastrointestinal side effects: a systematic review. Int J Gen Med. 2021;14:4757\u201363.","journal-title":"Int J Gen Med."},{"key":"1090_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jacc.2016.11.050","volume":"69","author":"DL Bhatt","year":"2017","unstructured":"Bhatt DL, Grosser T, Dong JF, et al. Enteric coating and aspirin nonresponsiveness in patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017;69:603\u201312.","journal-title":"J Am Coll Cardiol"},{"key":"1090_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1515\/afmnai-2015-0026","volume":"32","author":"P Randjelovi\u0107","year":"2015","unstructured":"Randjelovi\u0107 P, Veljkovi\u0107 S, Stojiljkovi\u0107 N, et al. The beneficial biological properties of salicylic acid. Acta facultatis medicae Naissensis. 2015;32:259\u201365.","journal-title":"Acta facultatis medicae Naissensis"},{"issue":"7","key":"1090_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/jnci\/djab008","volume":"113","author":"JC Figueiredo","year":"2021","unstructured":"Figueiredo JC, Jacobs EJ, Newton CC, Guinter MA, Cance WG, Campbell PT. Associations of aspirin and non-aspirin non-steroidal anti-inflammatory drugs with colorectal cancer mortality after diagnosis. J Natl Cancer Inst. 2021;113(7):833\u201340.","journal-title":"J Natl Cancer Inst"},{"key":"1090_CR13","doi-asserted-by":"crossref","unstructured":"Low-dose aspirin use during pregnancy. ACOG Committee Opinion No. 743. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;132:e44\u201352","DOI":"10.1097\/AOG.0000000000002708"},{"key":"1090_CR14","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1213\/ANE.0000000000005292","volume":"132","author":"JH Chow","year":"2021","unstructured":"Chow JH, Khanna AK, Kethireddy S, et al. Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. Anesth Analg. 2021;132:930\u201341.","journal-title":"Anesth Analg"},{"key":"1090_CR15","unstructured":"Vazalore Aspirin Drug Facts. Sparta, NJ: PLx Pharma Inc.; rev 5.17.2021"},{"key":"1090_CR16","unstructured":"Aspirin Professional Labeling. 21CFR343\u00c680. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=343&showFR=1. Accessed 20 Jul 2021."},{"key":"1090_CR17","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1093\/eurheartj\/ehv551","volume":"37","author":"M Scavone","year":"2016","unstructured":"Scavone M, Femia EA, Caroppo V, Cattaneo M. Inhibition of the platelet P2Y12 receptor for ADP does not impair the capacity of platelet to synthesize thromboxane A2. EHJ. 2016;37:3347\u201356.","journal-title":"EHJ"},{"key":"1090_CR18","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1161\/CIRCULATIONAHA.109.900589","volume":"120","author":"AL Frelinger 3rd","year":"2009","unstructured":"Frelinger AL 3rd, Li Y, Linden MD, et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009;120:2586\u201396.","journal-title":"Circulation"},{"issue":"3","key":"1090_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","volume":"88","author":"PA Gum","year":"2001","unstructured":"Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88(3):230\u20135.","journal-title":"Am J Cardiol"},{"key":"1090_CR20","first-page":"352","volume":"48","author":"A Papathanasiou","year":"2007","unstructured":"Papathanasiou A, Goudevenos J, Tselepis AD. Resistance to aspirin and clopidogrel: possible mechanisms, laboratory investigation, and clinical significance. Hellenic J Cardiol. 2007;48:352\u201363.","journal-title":"Hellenic J Cardiol"},{"key":"1090_CR21","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1021\/jm0613166","volume":"50","author":"AL Blobaum","year":"2007","unstructured":"Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. J Med Chem. 2007;50:1425\u201341.","journal-title":"J Med Chem"},{"key":"1090_CR22","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1358\/dot.2009.45.12.1441075","volume":"45","author":"LM Lichtenberger","year":"2009","unstructured":"Lichtenberger LM, Barron M, Marathi U. Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today (Barc). 2009;45:877\u201390.","journal-title":"Drugs Today (Barc)"},{"key":"1090_CR23","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.3892\/ol.2020.11817","volume":"20","author":"Z Li","year":"2020","unstructured":"Li Z, Wang Z, Shen B, Chen C, Ding X, Song H. Effects of aspirin on the gastrointestinal tract: Pros and cons (a Review). Onc Lett. 2020;20:2567\u201378.","journal-title":"Onc Lett"},{"key":"1090_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0889-8553(05)70247-8","volume":"25","author":"J Scheiman","year":"1996","unstructured":"Scheiman J. NSAIDS, Gastrointestinal Injury and Cytoprotection. Gastroent Clin NA. 1996;25:279\u201398.","journal-title":"Gastroent Clin NA"},{"key":"1090_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0016-5085(99)70545-7","volume":"117","author":"B Cryer","year":"1999","unstructured":"Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999;117:17\u201325.","journal-title":"Gastroenterology"},{"key":"1090_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1365-2036.2005.02649.x","volume":"22","author":"ND Yeomans","year":"2005","unstructured":"Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22:795\u2013801.","journal-title":"Aliment Pharmacol Ther"},{"key":"1090_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s10620-005-1281-1","volume":"50","author":"Y Niv","year":"2005","unstructured":"Niv Y, Battler A, Abuksis G, et al. Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci. 2005;50:78\u201380.","journal-title":"Dig Dis Sci"},{"key":"1090_CR28","doi-asserted-by":"crossref","unstructured":"Goldstein JL, Lowry SC, Lanza FL, et al. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective nonsteroidal anti-infl ammatory drug or a cyclo-oxygenase-2-selective inhibitor Aliment Pharmacol Ther 2006;23:1489 \u2013 98.","DOI":"10.1111\/j.1365-2036.2006.02912.x"},{"key":"1090_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1741-7015-4-22","volume":"4","author":"S Hernandez-Diaz","year":"2006","unstructured":"Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22.","journal-title":"BMC Med"},{"key":"1090_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/11584410-000000000-00000","volume":"10","author":"S Pratt","year":"2010","unstructured":"Pratt S, Thompson VJ, Elkin EP, N\u00e6sdal J, S\u00f6rstadius E. The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs. 2010;10:281\u20138.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1090_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cpcardiol.2017.01.006","volume":"42","author":"CJ LaVie","year":"2017","unstructured":"LaVie CJ, Howden CW, Scheiman J, Tursi J. Upper gastrointestinal toxicity associated with long-term aspirin therapy: consequences and prevention. Curr Prob Cardiol. 2017;42:146\u201364.","journal-title":"Curr Prob Cardiol."},{"key":"1090_CR32","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.bbalip.2012.04.002","volume":"1821","author":"L Lichtenberger","year":"2012","unstructured":"Lichtenberger L. Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: characterization of interaction of NSAIDS with phosphatidylcholine. Biochim Biophys Acta. 2012;1821:994\u20131002.","journal-title":"Biochim Biophys Acta"},{"key":"1090_CR33","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10620-012-2530-8","volume":"58","author":"L Lichtenberger","year":"2013","unstructured":"Lichtenberger L. Role of phospholipids in protection of the GI Mucosa. Dig Dis Sci. 2013;58:891\u20133.","journal-title":"Dig Dis Sci"},{"key":"1090_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrgastro.2011.97","volume":"8","author":"C Sostres","year":"2011","unstructured":"Sostres C, Lanas A. Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol. 2011;8:385\u201394.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1090_CR35","first-page":"5","volume":"2","author":"NM Davies","year":"1999","unstructured":"Davies NM. Sustained release and enteric coated NSAIDs: are they really GI safe? J Pharm Pharm Sci. 1999;2:5\u201314.","journal-title":"J Pharm Pharm Sci"},{"key":"1090_CR36","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3109\/00365521.2011.568522","volume":"46","author":"Y Hirata","year":"2011","unstructured":"Hirata Y, Kataoka H, Shimura T, et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol. 2011;46:803\u20139.","journal-title":"Scand J Gastroenterol"},{"key":"1090_CR37","first-page":"3002","volume":"64","author":"G Levy","year":"1964","unstructured":"Levy G, Hollister LE. Failure of USP disintegration test to assess physiologic availability of enteric coated tablets. NY State J Med. 1964;64:3002\u20135.","journal-title":"NY State J Med."},{"key":"1090_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1001\/jama.1965.03090020013004","volume":"193","author":"JR Leonardis","year":"1965","unstructured":"Leonardis JR. Absorption and metabolism of aspirin administered in enteric-coated tablets. JAMA. 1965;193:99\u2013104.","journal-title":"JAMA"},{"key":"1090_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/BF00611905","volume":"14","author":"C Bogentoft","year":"1978","unstructured":"Bogentoft C, Carlsson I, Ekenved G, Magnusson A. Influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms. Eur J Clin Pharmacol. 1978;14:351\u20135.","journal-title":"Eur J Clin Pharmacol"},{"key":"1090_CR40","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/BF00558267","volume":"35","author":"F Bochner","year":"1988","unstructured":"Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV. PK of low-dose oral modified release, soluble and IV aspirin in man, and effects on platelet function. Eur J Clin Pharmacol. 1988;35:287\u201394.","journal-title":"Eur J Clin Pharmacol"},{"key":"1090_CR41","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bcpt.12362","volume":"116","author":"PF Haastrup","year":"2015","unstructured":"Haastrup PF. Enteric coating can lead to reduced antiplatelet effect of low-dose acetylsalicylic acid. Basic Clin Pharmacol Toxicol. 2015;116:212\u20135.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1090_CR42","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/cpt.874","volume":"103","author":"D Cox","year":"2018","unstructured":"Cox D, Fitzgerald DJ. Lack of bioequivalence among low-dose, enteric coated aspirin preparations. Clin Pharmacol Ther. 2018;103:1047\u201351.","journal-title":"Clin Pharmacol Ther"},{"key":"1090_CR43","unstructured":"Cleveland Clinic. Aspirin Therapy in Heart Disease. https:\/\/my.clevelandclinic.org\/health\/drugs\/16761-aspirin-therapy-in-heart-disease. Accessed 20 Jun 2021."},{"key":"1090_CR44","unstructured":"Harvard Medical. Answers about aspirin. https:\/\/www.health.harvard.edu\/heart-health\/answers-about-aspirin. Accessed 20 Jun 2021."},{"key":"1090_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5009\/gnl.2013.7.1.7","volume":"7","author":"YJ Lim","year":"2013","unstructured":"Lim YJ, Dial EJ, Lichtenberger LM. Advent of novel phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs with improved gastrointestinal safety. Gut Liver. 2013;7:7\u201315.","journal-title":"Gut Liver"},{"key":"1090_CR46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2036.2008.03765.x","volume":"28","author":"BS Anand","year":"2008","unstructured":"Anand BS, Romero JJ, Sanduja SK, Lichtenberger LM. Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Aliment Pharmacol Ther. 2008;28:431\u201342.","journal-title":"Aliment Pharmacol Ther"},{"key":"1090_CR47","unstructured":"PLx Pharma. Data on file."},{"key":"1090_CR48","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s11239-019-01933-7","volume":"48","author":"DJ Angiolillo","year":"2019","unstructured":"Angiolillo DJ, Bhatt DL, Lanza F, et al. Pharmacokinetic\/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. J Thromb Thrombolysis. 2019;48:554\u201362.","journal-title":"J Thromb Thrombolysis"},{"key":"1090_CR49","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11239-020-02051-5","volume":"49","author":"DJ Angiolillo","year":"2020","unstructured":"Angiolillo DJ, Bhatt DL, Lanza F, et al. Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation. J Thromb Thrombolysis. 2020;49:337\u201343.","journal-title":"J Thromb Thrombolysis"},{"key":"1090_CR50","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/ajg.2010.436","volume":"106","author":"B Cryer","year":"2011","unstructured":"Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011;106:272\u20137.","journal-title":"Am J Gastroenterol"},{"key":"1090_CR51","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0140-6736(65)92781-9","volume":"1","author":"JW Kerr","year":"1965","unstructured":"Kerr JW, Macaulay I, Pirrie R, Bronte-Stewart B. Platelet aggregation by phospholipids and free fatty acids. Lancet. 1965;1:1296\u20139.","journal-title":"Lancet"},{"key":"1090_CR52","first-page":"326","volume":"13","author":"G Hornstra","year":"1977","unstructured":"Hornstra G. Dietary fats and arterial thrombosis: effects and mechanism of action. Prog Biochem Pharmacol. 1977;13:326\u201338.","journal-title":"Prog Biochem Pharmacol"},{"key":"1090_CR53","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0005-2736(85)90032-X","volume":"817","author":"T Kobayashi","year":"1985","unstructured":"Kobayashi T, Yamada J, Satoh N, Setaka M, Kwan T. Inhibition of platelet aggregation by synthetic phosphatidylcholines: possible involvement of vesiculation of platelet plasma membranes. Biochim Biophys Acta. 1985;817:307\u201312.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"1090_CR54","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/FJC.0000000000000998","volume":"78","author":"DJ Schneider","year":"2021","unstructured":"Schneider DJ, Taatjes-Sommer HS, Prats J, Deliargyris EN. Influence of lipid excipients on platelet function and the pharmacodynamic effects of aspirin. J Cardiovasc Pharmacol. 2021;78(2):297\u2013301.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1090_CR55","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/jps.2600610312","volume":"61","author":"M Rowland","year":"1972","unstructured":"Rowland M, Riegelman S, Harris PA, Sholkoff SD. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci. 1972;61:379\u201385.","journal-title":"J Pharm Sci"},{"key":"1090_CR56","doi-asserted-by":"publisher","unstructured":"Graham GG, Day RO. Salicylates. In: Parnham M (ed). Compendium of Inflammatory Diseases. Basel: Birkh\u00e4user; 2016. https:\/\/doi.org\/10.1007\/978-3-0348-0620-6_62-3.","DOI":"10.1007\/978-3-0348-0620-6_62-3"},{"key":"1090_CR57","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.jacc.2005.08.014","volume":"46","author":"DJ Schneider","year":"2005","unstructured":"Schneider DJ. On defining aspirin resistance. J Am Coll Cardiol. 2005;46:1710\u20131.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1090_CR58","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1161\/CIRCULATIONAHA.112.117283","volume":"127","author":"T Grosser","year":"2013","unstructured":"Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013;127(3):377\u201385.","journal-title":"Circulation"},{"key":"1090_CR59","first-page":"1183","volume":"136","author":"J Sundstrom","year":"2017","unstructured":"Sundstrom J, Hedberg J, Thuresson M, Aarskog P, Johannesen KM, Oldgren J. Low-dose aspirin discontinuation and risk of cardiovascular events. A Swedish Nationwide. Population-Based Cohort Study Circulation. 2017;136:1183\u201392.","journal-title":"Population-Based Cohort Study. Circulation."},{"key":"1090_CR60","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0735-1097(20)31971-9","volume":"75","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Angiolillo DA, Steg PG, et al. Impact of weight on the antiplatelet effects of aspirin-results of a pooled analysis of two randomized crossover studies comparing a liquid aspirin formulation with enteric-coated aspirin. J Am Coll Cardiol. 2020;75:1344.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1090_CR61","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ehj.2003.10.024","volume":"25","author":"D De Bacquer","year":"2004","unstructured":"De Bacquer D, De Backer G, Cokkinos D, Keil U, Montaye M, Ost\u00f6r E, et al. Overweight and obesity in patients with established coronary heart disease: are we meeting the challenge? Eur Heart J. 2004;25(2):121\u20138.","journal-title":"Eur Heart J"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01090-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01090-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01090-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T16:04:55Z","timestamp":1666541095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01090-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1090"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01090-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"1 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for PK-PD studies described in this manuscript, for Open Access of this article\u00a0and for illustrations was provided by PLx Pharma, Inc.\u00a0","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Angiolillo is a member of the PLx Pharma Scientific Advisory Board has received payment as an individual for: a) Consulting fee or honorarium from Abbott, Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; b) Participation in review activities from CeloNova and St. Jude Medical; c) Institutional payments for grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli-Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal Guard Solutions and the Scott R. MacKenzie Foundation.\nDr. Prats is a consultant to PLxPharma, manufacturer of PL-ASA (Vazalore)\nDr. Deliargyris is a member of the PLx Pharma Scientific Advisory Board, no other relevant conflicts.\nDr. Schneider has received grant funding from Plx Pharma.\nDr. Scheiman is a member of the PLx Pharma Scientific Advisory Board and consultant, Tremeau Pharmaceuticals.\nDr. Kimmelstiel is a member of the PLx Pharma Scientific Advisory Board, no other relevant conflicts.\nDr. Steg is a member of the PLx Pharma Scientific Advisory Board. He reports research grants from Amarin, Bayer, Sanofi, and Servier; clinical trial conduct (Steering committee, CEC, DSMB) with Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Idorsia, Novartis, Pfizer, Sanofi, Servier; consulting or speaking activity for Amgen, BMS\/Myokardia, Novo-Nordisk, Regeneron ; and is a Senior Associate Editor at Circulation.\nDr. Alberts is a member of the PLx Pharma Scientific Advisory Board, no other relevant conflicts.\nDr. Rosengart is a member of the PLx Pharma Scientific Advisory Board, no other relevant conflicts.\nDr. Mehran reports institutional research grants from Abbott, Abiomed, Applied Therapeutics, Arena, AstraZeneca, Bayer, Biosensors, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CellAegis, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Insel Gruppe AG, Medtronic, Novartis Pharmaceuticals, OrbusNeich, Philips, Transverse Medical, Zoll; personal fees from ACC, Boston Scientific, California Institute for Regenerative Medicine (CIRM), Cine-Med Research, Janssen, WebMD, SCAI; consulting fees paid to the institution from Abbott, Abiomed, AM-Pharma, Alleviant Medical, Bayer, Beth Israel Deaconess, CardiaWave, CeloNova, Chiesi, CSL Behring, Concept Medical, DSI, Duke University, Idorsia Pharmaceuticals, Medtronic, Novartis, Philips; Equity <1% in Applied Therapeutics, Elixir Medical, STEL, CONTROLRAD (spouse); Scientific Advisory Board for AMA, Biosensors (spouse); Faculty CRF (no fee). Dr. Deepak L. Bhatt discloses the following relationships - Advisory Board: Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence\/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today\u2019s Intervention), Society of Cardiovascular Patient Care (Secretary\/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, The Medicines Company, 89Bio; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald\u2019s Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Philips, Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Takeda.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}